Advances in the management of ALK-rearranged NSCLC

Sponsored by Takeda Pharmaceuticals

The introduction of anaplastic lymphoma kinase (ALK) inhibitors has dramatically improved patient survival and quality of life in patients with ALK-rearranged (or ALK+) non-small cell lung cancers (NSCLC).1 There are now a number of ALK inhibitors available in Australia for first-line treatment of ALK+ NSCLC, including the second-generation ALK inhibitor brigatinib.2 The limbic spoke to ...

Already a member?

Login to keep reading.

© 2022 the limbic